FridayFeb 02, 2024 4:20 am

420 with CNW — Poll Suggests 32% of Americans Would Resort to Black Market If Cannabis Only Available in Pharmacies

A recent poll indicates that almost one-third of marijuana consumers nationwide would return to purchasing from illegal sources if marijuana were to be rescheduled without preserving legal state marketplaces. The survey, conducted by a website that facilitates medical cannabis physician evaluations, involved nearly 800 respondents. NuggMD.com reported that its survey findings showed that if cannabis was rescheduled, restricting its legal access to FDA-approved prescription medications, 32% of participants would head to the black market. An estimated 55% of respondents preferred using pharmacies to obtain cannabis, indicating a large preference for legal sources. Last year, the U.S. Department of Health and…

Continue Reading

ThursdayFeb 01, 2024 4:20 pm

420 with CNW — Cannabis MSOs Set Sights on Growing Wholesale Divisions

A top cannabis executive recently revealed that several cannabis multistate operators (MSOs) intend to prioritize their wholesale divisions in 2024. Jamie Mendola, the national head of wholesale/purchasing, western region regional manager and chief business development officer at Florida-based multistate operator Ayr Wellness, says that while MSOs focused on wholesale last year, the division will become an even greater priority this year. Mendola notes that reduced capital will decrease the odds of company growth through mergers and acquisitions or by obtaining more licenses, forcing MSOs to turn their focus to wholesale. He adds that with many vertically integrated cannabis businesses in…

Continue Reading

ThursdayFeb 01, 2024 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces 2024 GLP-1 Human and Animal Studies Roadmap

Lexaria, a global innovator in drug delivery platforms, has laid down its GLP-1 human and animal studies roadmap for the 2024 calendar year This builds on the success of its human pilot study, which marked a successful undertaking for exploring its patented DehydraTECH(TM) technology for the improved delivery of the GLP-1 drug semaglutide, available commercially in the branded product Rybelsus(R) The company’s chronic dosing animal study and its second human pilot study will commence in Spring and run for 12 weeks. The third human pilot study will start in May or June These studies will evaluate DehydraTECH for the improved…

Continue Reading

ThursdayFeb 01, 2024 4:20 am

420 with CNW — Federal Judge Upholds Medical Cannabis Advertising Restrictions

A lawsuit filed against the state of Mississippi by a medical cannabis dispensary owner has been dismissed. The lawsuit challenged Mississippi’s laws, which the plaintiff said placed restrictions on marijuana businesses by forbidding them from placing advertisements on a majority of media platforms. In a decision issues last week, Federal District Judge Michael P. Mills agreed with the state’s stance that such operations do not benefit from the constitutional protections afforded to certain types of commercial speech because marijuana possession is still prohibited under federal law. Clarence Cocroft II, the plaintiff, founded Tru Source Medical Cannabis in 2022 following Mississippi’s…

Continue Reading

Official NewsWire Relationships

Alternative Products Expo Benzinga Cannabis Capital Conference Cannabis Business Summit & Expo 2019 Cannabis Drinks Expo Cannabis World Congress & Business Exposition Cannexpo Marigold PR MjMicro Conference New England Cannabis Network O'Cannabiz Conference & Expo Tether BudTender Tether BudTender Appreciation Week

CannabisNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722